Baseline organ dysfunction precluding standard cisplatin-based chemotherapy or affecting...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-SALIVARY-ORGAN-DYSFUNCTION`
Type	Signal d’alerte
État	reviewed 2026-04-27 \| pending_clinical_signoff
Maladies	`DIS-SALIVARY`
Sources	`SRC-ESMO-SALIVARY` `SRC-NCCN-HEAD-AND-NECK`

Origine du drapeau rouge

Définition	Baseline organ dysfunction precluding standard cisplatin-based chemotherapy or affecting targeted therapy in advanced salivary gland carcinoma: CrCl <60 mL/min (cisplatin contraindicated, switch to carboplatin), LVEF <50% (trastuzumab contraindicated for HER2+ SDC, doxorubicin in adenoid-cystic chemo), bilirubin >3× ULN (taxane / TKI hepatic clearance), baseline ototoxicity (cisplatin contraindicated), or QTc >480 ms (entrectinib / tipifarnib QT signal).
Direction clinique	désescalade
Catégorie	dysfonction d'organe

Logique de déclenchement

{
  "any_of": [
    {
      "comparator": "<",
      "finding": "creatinine_clearance_ml_min",
      "threshold": 60
    },
    {
      "comparator": "<",
      "finding": "lvef_percent",
      "threshold": 50
    },
    {
      "comparator": ">=",
      "finding": "bilirubin_ratio_to_uln",
      "threshold": 3
    },
    {
      "finding": "baseline_ototoxicity",
      "value": true
    },
    {
      "comparator": ">",
      "finding": "qtc_ms",
      "threshold": 480
    }
  ],
  "type": "lab_value"
}

Notes

Cisplatin-based chemotherapy in salivary gland cancer has only modest activity (ORR ~30% in mucoepidermoid / adenoid cystic) — the organ- dysfunction flag pushes harder toward histology-specific targeted therapy when biomarker-positive. HER2+ SDC: trastuzumab + chemotherapy requires baseline LVEF ≥50% (analogous to breast cancer protocols). Larotrectinib / entrectinib for NTRK+ MASC well-tolerated; entrectinib has documented QT prolongation. Tipifarnib (HRAS+ SDC) carries cytopenias + QT prolongation. AR-targeted therapy (bicalutamide + LHRH) generally well-tolerated even with organ dysfunction — a viable de-escalation path for AR+ SDC.

Utilisé par

No reverse references found in the YAML corpus.